AR and hypoparathyroidism-retardation-dysmorphism syndrome: Among them, AR, and its splicing variant AR-V7, synaptophysin, chromogranin, or CD56 (for NEPC), homologous recombination deficiency (HRD), and prostate-specific membrane antigens (PSMAs) are employed for novel therapeutic approaches, including poly ADP ribose polymerase (PARP) inhibitors.